Aralez Pharmaceuticals Inc

Aralez Pharmaceuticals — Bloom Burton Healthcare Conference 2016

15 slides from Aralez Pharmaceuticals's conference presentation, May 2, 2016

  1. Slide 1: Forward-looking statements

    Slide 1: Forward-looking statements

    This presentation includes certain statements that constitute “forward-looking statements” within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding our 2016 financial guidance, the anticipated launch of BLEXTEN, promotional an

  2. Slide 2: The Aralez Investment Thesis

    Slide 2: The Aralez Investment Thesis

    The Aralez Investment Thesis Aralez is a new global specialty pharmaceutical company designed to: Maximize the value of an expanded portfolio, growing revenue base and geographic footprint across North America and Europe Build on our anchor positions in cardiovascular disease and pain management and

  3. Slide 3: Focus on Cardiovascular & Pain Therapies

    Slide 3: Focus on Cardiovascular & Pain Therapies

    Focus on Cardiovascular & Pain Therapies VIMOVO®: (partnered): Combination of esomeprazole and naproxen for osteoarthritis in patients at risk of developing NSAID associated gastric ulcers Horizon Pharma (US) – 10% on US sales; annual minimum of $7.5M; Patented until 2031 AstraZeneca (ex-US) – 50+ c

  4. Slide 4: Fibricor: Commercialization Strategy

    Slide 4: Fibricor: Commercialization Strategy

    Fibricor®: Commercialization Strategy Detail efficacy and safety of Fibricor Drive broader utilization among targets and educate HCPs on how to Rx Capitalize on coverage and affordability with copay program Leverage affordability and flexibility of brand and AG Increase pharmacy touch points to faci

  5. Slide 5: Secondary prevention patient population and YOSPRALA share opportunity

    Slide 5: Secondary prevention patient population and YOSPRALA share opportunity

    18.3M 70% take aspirin2 6.3M take aspirin plus PPI/H23 26.2M secondary prevention patients1 Could achieve Mid Single Digit Market Share in the Secondary Prevention Patient Population Current vs. Future Prescribing Preference for Secondary Prevention Patients Q. (n=268) Thinking of your secondary pre

  6. Slide 6: YOSPRALA: Commercialization Strategy

    Slide 6: YOSPRALA: Commercialization Strategy

    YOSPRALA: Commercialization Strategy Upon FDA approval, plan to launch YOSPRALA with ~110 sales professionals (including 25 previously hired for Fibricor), targeting top 29% of secondary prevention specialist (CV, IM and PCP) physicians; Target ~15,000 physicians initially, including 8,000 cardiolog

  7. Slide 7: YOSPRALA: Pre-Launch Preparations

    Slide 7: YOSPRALA: Pre-Launch Preparations

    YOSPRALA: Pre-Launch Preparations Confirmed launch pricing for YOSPRALA Received feedback from KOL, Professional, and Advocacy groups Developed comprehensive and logical commercial messaging platform Developed and tested compelling branded and unbranded platforms Received positive feedback regarding

  8. Slide 8: Disease Awareness Initiative

    Slide 8: Disease Awareness Initiative

    Disease Awareness Initiative Key Communication Goals: Raise awareness among prescribers of the gastrointestinal (GI) side effects of aspirin and their impact on outcomes There may be a hole in his aspirin therapy Journals Ads Website Direct Mail Banner Ads E-blast

  9. Slide 9: Tribute History: A Canadian Growth Story

    Slide 9: Tribute History: A Canadian Growth Story

    Tribute History: A Canadian Growth Story Tribute, a Canadian specialty pharmaceutical company, founded in January 2006 as a private company Strong history of growth through value-creating acquisitions and partnerships Collatamp® G in May 2012 Bilastine in May 2014 Fiorinal®, Fiorinal® C, Visken® & V

  10. Slide 10: BLEXTEN - New Product Opportunity in Canada

    Slide 10: BLEXTEN - New Product Opportunity in Canada

    BLEXTEN™ - New Product Opportunity in Canada BLEXTEN (bilastine 20 mg oral tablet) is a second generation antihistamine drug for the treatment of the symptoms of Seasonal Allergic Rhinitis (SAR) and Chronic Spontaneous Urticaria (CSU) (such as itchiness and hives) developed in Spain by FAES Farma, S

  11. Slide 11: Aralez: Canadian Portfolio Growth Drivers

    Slide 11: Aralez: Canadian Portfolio Growth Drivers

    Aralez: Canadian Portfolio Growth Drivers Cambia® Exclusive license in Canada from Depomed, Inc. Cambia (diclofenac) was approved by Health Canada in 2009 for the acute treatment of migraine attached with or without aura in adults 18 years of age or older Durela® Exclusive license in Canada from Cip

  12. Slide 12: 2016 Financial Guidance

    Slide 12: 2016 Financial Guidance

    2016 Financial Guidance Measure 2016 Guidance Net Revenues* $48 million to $58 million Non-GAAP SG&A Expenses** $85 million to $100 million Non-GAAP R&D Expenses ** $8 million to $12 million * Guidance on net revenues includes revenues from Tribute from February 6, 2016 through December 31, 2016, as

  13. Slide 13: Aralez - Our Near Term Priorities

    Slide 13: Aralez - Our Near Term Priorities

    Aralez - Our Near Term Priorities Continued financially disciplined build up of organization Commercial execution of the recent promotional launch of Fibricor YOSPRALA PDUFA goal date of September 14, 2016; target launch in 4Q 2016, pending FDA approval Plan to submit YOSPRALA in Europe in 3Q 2016 a

  14. Slide 14: Corporate Overview & Strategic Vision

    Slide 14: Corporate Overview & Strategic Vision

    “Corporate Overview & Strategic Vision” Bloom Burton Healthcare Conference May 2, 2016

  15. Slide 15: Breathing New Life Into Pharmaceuticals

    Slide 15: Breathing New Life Into Pharmaceuticals

    -rale2 Pharmaceuticals Breathing New Life Into Pharmaceuticals™ Bloom Burton Healthcare Conference “Corporate Overview & Strategic Vision” May 2, 2016

Source: SEC EDGAR · 8-K filed May 2, 2016

More decks from Aralez Pharmaceuticals Inc